Latest news with #AlembicPharma
&w=3840&q=100)
Business Standard
06-08-2025
- Business
- Business Standard
Alembic Pharma dips 3% post Q1 results; MOFSL retains Neutral, here's why
Alembic Pharma share price today: Shares of Vadodara-based pharmaceutical company Alembic Pharma fell around 3.5 per cent on Wednesday, on the NSE, after the company reported its June 2025 quarter (Q1FY26) results. The stock touched an intraday low of ₹913.4. At 1:35 PM, Alembic was trading 1.7 per cent lower at ₹931 on the NSE. In comparison, the NSE Nifty was trading lower by 0.13 per cent at 24,618.45. The stock has crashed around 27 per cent from its 52-week high of ₹1,303.9 touched on October 9, 2024. CATCH STOCK MARKET UPDATES TODAY LIVE In addition, the overall muted sentiment around pharma stocks after US President Donald Trump hinted at as much as a 250 per cent tariff rate in 12 to 18 months also impacted the stock. The Nifty Pharma index fell as much as 1.8 per cent on Wednesday. Alembic Pharmaceuticals Q1 results The company reported a 14 per cent increase in consolidated net profit year-on-year (Y-o-Y) to ₹154.33 crore for the Q1FY26 compared to ₹131.21 crore in the year-ago period. Revenue from operations also rose by 10 per cent Y-o-Y to ₹1,710.72 crore against ₹1,561.73 crore in Q1FY25. Alembic's India branded business witnessed 5 per cent Y-o-Y growth to ₹599 crore in the quarter under review. United States generic revenue also grew 13 per cent to ₹523 crore, on the back of four new launches in the market. The company secured six abbreviated new drug application (ANDA) approvals during the quarter, bringing total approvals to 223. The active pharmaceutical ingredient (API) business grew marginally by 1 per cent, with revenue of ₹261 crore for the quarter. Alembic Pharma Q1 results analysis - Motilal Oswal Financial Services According to analysts at MOFSL, Alembic Pharma delivered a largely in-line performance for 1QFY26 as superior execution in the export market led to Y-o-Y growth in revenue/Ebitda/PAT for the quarter. However, this growth was offset, to some extent, by a muted show in the domestic formulation (DF) and API segments. Alembic Pharma maintained its growth momentum in the US market on the back of new launches. Notably, upcoming introductions such as g-Entresto have the potential to further strengthen growth in the US generics segment. That said, a broader scope of business would be necessary to enhance capacity utilisation and, in turn, improve the profitability of the US generics segment, MOFSL said in a note. "After a muted performance in FY25, ALPM is working to improve business prospects across its key markets. Growth in export markets is strengthening on the back of new launches and superior supply chain management. Considering these aspects, we expect a 24 per cent earnings compound annual growth rate (CAGR) over FY25-27. The current valuation largely factors in the earnings upside," the brokerage said. MOFSL has maintained a 'Neutral' rating on the stock with a target price of ₹990. About Alembic Pharma Incorporated in 2010, Alembic Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, including formulations and active pharmaceutical ingredients. Its products can be broadly classified into active pharmaceutical ingredients (APIs), formulations, and international generics. Alembic's customers include pharmaceutical companies for APIs, healthcare facilities and patients for formulations, and healthcare facilities and patients for international generics. It has presence across 33 states and union territories in India and 78 countries globally.
Business Upturn
17-06-2025
- Business
- Business Upturn
Pharma stocks in focus as Trump announces tariffs on sector ‘soon'
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenue exposure include Alembic Pharma (50%+), Aurobindo Pharma (45%+), and Dr. Reddy's and Zydus (both 40%). These firms are likely to be the most impacted if tariffs are introduced or raised on pharmaceutical imports from India. Here's a quick look at U.S. revenue exposure for key Indian pharma companies: Company % Revenue from U.S. Alembic 50%+ Aurobindo 45%+ Dr. Reddy's 40% Zydus 40% Lupin 34–38% Sun Pharma 30–35% Glenmark 30% Cipla 25–30% Torrent ~15–20% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Mint
11-06-2025
- Business
- Mint
Alembic Pharma shares rise after announcement of record date for dividend payment. Details here
Alembic Pharma share price rose nearly 2% following the declaration of the record date for dividend distribution. Alembic Pharmaceuticals has set Tuesday, 29th July, 2025, as the record date to identify the members eligible to receive dividends for the financial year concluding on 31st March, 2025. The dividend will be paid on or after Thursday, 7th August, 2025, following its approval at the Annual General Meeting planned for 5th August, 2025, as stated by the company in its filing to the exchange.
Reuters
20-05-2025
- Business
- Reuters
India's Zydus Life reports higher quarterly profit on new drug launches in US
May 20 (Reuters) - Indian drugmaker Zydus Lifesciences ( opens new tab reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market. The company reported a 22% rise in its consolidated profit before exceptional items and tax to 18.92 billion rupees ($221.3 million) for the quarter ended March 31. However, Zydus Life recorded an exceptional item worth 2.20 billion rupees due to an impairment charge tied to its Brazil business and the closure of operations at one of the facilities of its unit Zydus Wellness ( opens new tab. Including the charge, its consolidated net profit fell 1% year-on-year. Overall revenue climbed 18%, led by a 24% growth in U.S. sales and 13% jump in India sales. Zydus Life, like most Indian generic drugmakers, derives a large chunk of its revenue from the U.S. New drug launches, especially in the specialty portfolio, led to strong growth in U.S., Zydus Life said. It launched five new products during the quarter across therapy areas such as diabetes and anti-infectives. Peer Alembic Pharma ( opens new tab reported a higher quarterly profit, while larger rival Cipla ( opens new tab and Dr Reddy's ( opens new tab beat profit estimates as they all benefited from strong domestic demand for their drugs. PEER COMPARISON * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT JANUARY TO MARCH STOCK PERFORMANCE -- All data from LSEG -- $1 = 85.4960 Indian Rupees
Reuters
06-05-2025
- Business
- Reuters
India's Alembic Pharma's quarterly profit drops on tax expense
May 6 (Reuters) - Indian drugmaker Alembic Pharmaceuticals ( opens new tab reported a 12% fall in fourth-quarter profit on Tuesday, hurt by a deferred tax expense that offset the impact of strong sales in its key U.S. and domestic markets. The company's consolidated profit fell to 1.57 billion rupees (nearly $19 million) in the quarter ended March 31, from 1.78 billion rupees a year ago. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. It recorded a deferred tax expense of 146.7 million rupees compared with a tax gain of 217.5 million rupees a year earlier. Its profit before tax climbed 5%. Alembic Pharma's sales in the U.S. climbed 20%, while sales in India rose 8%. This drove its overall revenue 17% higher to 17.70 billion rupees. KEY CONTEXT A large chunk of revenues for most Indian generic drugmakers comes from the U.S. While fierce competition in North America's generic drugs market has been weighing on some firms' margins, generic drugmakers are also under threat from U.S. President Donald Trump tariff plans for the sector. PEER COMPARISON * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT JANUARY TO MARCH STOCK PERFORMANCE -- All data from LSEG -- $1 = 84.3825 Indian rupees
